Innovent/Lilly’s Sintilimab, Developed In China, May Be Headed For Troubled US Waters

 
• By Sue Sutter
Bridge over water
Multiregional trials will be the true 'bridge' for global drug development and regulatory harmonization, FDA oncology leaders say. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers